[Chemotherapy with MTX, 5-FU and CDGP for treatment of newly diagnosed head and neck cancer].
Combination chemotherapy including 5-fluorouracil (5-FU) and nedaplatin (CDGP) with methotrexate (MTX) and leucovorin(LV)as biochemical modulators was performed on patients with newly diagnosed head and neck cancer. We treated 45 patients with MTX, 5-FU and CDGP consisting of 150 mg/body of MTX on day 1 followed by a 3-day continuous infusion of 5-FU at 3,500 mg/m2 and 17 injections of LV at 15 mg and infusion of CDGP at 100 mg/m2. Forty-three patients were concurrently treated with radiotherapy. Seven of the 45 had distant metastasis. In spite of the metastasis, 6 of the 7 underwent radiation therapy only on the primary or cervical metastatic mass because their primary tumor was bulky. Treatment-associated toxicities, e. g., mucositis and myelosuppression were significant but acceptable. The overall response rate was 97.6% with 61.9% of CR.
Sakoda
Takema
T
Dept. of Otorhinolaryngology, Rinku General Medical Center, Izumisano Municipal Hospital.
Morizane
Rie
R
Nakahara
Kei
K
Enomoto
Yumiko
Y
Nosaka
Aya
A
Enomoto
Tadao
T
Kitano
Hiroya
H
D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009944:Organoplatinum Compounds / Q000008:administration & dosage
D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; C053989:nedaplatin; D005472:Fluorouracil; D008727:Methotrexate